CHARVERIAT, Mathieu; DARMONI, Stephan J.; LAFON, Vincent; MOORE, Nicholas; BORDET, Regis; VEYS, Julien; MOUTHON, Franck; GROUP, Sfpt Translational Research In Pharmacology

doi:10.1111/fcp.12734

Métadonnées

Afficher la notice complète

Licence d’utilisation du document

Langue

Article de revue

Ce document a été publié dans

Fundamental & Clinical Pharmacology. 2021-10-21

Résumé en anglais

Real-world evidence (RWE) refers to observational data gathered outside the formalism of randomized controlled trials, in real life situations, on marketed drugs. While clinical trials are the gold standards to demonstrate the efficacy and tolerability of a medicinal product, the generalizability of their results to actual use in real-life is limited by the biases induced by the very nature of clinical trials; indeed, the patients included in the trials may differ from actual users because of their concomitant diseases or treatments, or other factors excluding them from the trials. Clinical researchers and pharmaceutical industries have hence become increasingly interested in expanding and integrating RWE into clinical research, by capitalizing on the exponential growth in access to data from electronic health records, claims databases, electronic devices, software or mobile applications, registries embedded in clinical practice and social media. Meanwhile, applications of RWE may also be used for drug discovery and repurposing, for clinical developments and post-marketing studies. The aim of this review is to provide our opinion regarding the use of RWE in translational research, including non-clinical and clinical pharmacology research, at the different step of drugs development use.< Réduire

Métadonnées

Partager cette publication !

Licence d’utilisation du document

Use of real-world evidence in translational pharmacology research

Langue

Ce document a été publié dans

Résumé en anglais

URI

DOI

Unités de recherche